Business Context and Reporting Period
Company: TNF Pharmaceuticals, Inc. (TNFA)
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2024
Reporting Period: Event-based report regarding corporate governance and capital structure amendments.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt levels, or liquidity metrics. The document focuses exclusively on the amendment of a securities agreement.
Material Changes
- Amendment to Series G Convertible Preferred Stock: On August 8, 2024, the Company entered into an Amendment Agreement with Required Holders to amend the Certificate of Designations for its Series G Convertible Preferred Stock.
- Dividend Calculation Adjustment: The amendment specifically modifies the methodology used to determine the number of shares of Preferred Stock to be issued for the payment of dividends "in kind" (additional shares of Preferred Stock).
- Regulatory Filing: The Company filed the Certificate of Amendment with the Delaware Secretary of State on August 8, 2024, making the changes effective immediately upon filing.
Guidance, Outlook, and Risks
Management Commentary: The filing references a Securities Purchase Agreement (SPA) entered into on May 20, 2024, with accredited investors for the sale of Series G Convertible Preferred Stock and warrants. The current amendment clarifies the mechanics of in-kind dividend distributions under this agreement.
Risks and Contingencies: The filing notes that the descriptions of the Agreement and Certificate of Amendment are qualified in their entirety by reference to the full text of the documents filed as Exhibits 10.1 and 3.1. No specific new risks or contingencies are detailed in the summary text of this 8-K.
Investor Verification Checklist
- Review Exhibit 3.1 (Certificate of Amendment) to understand the precise mathematical or procedural changes to the in-kind dividend calculation.
- Examine Exhibit 10.1 (Amendment Agreement) for any additional covenants or conditions imposed by the Required Holders.
- Verify the total outstanding shares of Series G Convertible Preferred Stock to assess the potential dilution impact of future in-kind dividends under the new formula.
- Confirm the status of the original May 20, 2024, Securities Purchase Agreement to ensure all terms remain consistent with the amendment.